Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Cash & Current Investments (2016 - 2025)

Historic Cash & Current Investments for Summit Therapeutics (SMMT) over the last 10 years, with Q3 2025 value amounting to $238.9 million.

  • Summit Therapeutics' Cash & Current Investments rose 15385.77% to $238.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $238.9 million, marking a year-over-year increase of 15385.77%. This contributed to the annual value of $412.3 million for FY2024, which is 12140.49% up from last year.
  • As of Q3 2025, Summit Therapeutics' Cash & Current Investments stood at $238.9 million, which was up 15385.77% from $298.2 million recorded in Q2 2025.
  • Over the past 5 years, Summit Therapeutics' Cash & Current Investments peaked at $648.6 million during Q4 2022, and registered a low of $28.8 million during Q2 2024.
  • For the 5-year period, Summit Therapeutics' Cash & Current Investments averaged around $211.6 million, with its median value being $192.6 million (2023).
  • Its Cash & Current Investments has fluctuated over the past 5 years, first crashed by 8662.69% in 2024, then soared by 93704.18% in 2025.
  • Over the past 5 years, Summit Therapeutics' Cash & Current Investments (Quarter) stood at $71.8 million in 2021, then surged by 803.47% to $648.6 million in 2022, then plummeted by 71.29% to $186.2 million in 2023, then skyrocketed by 121.4% to $412.3 million in 2024, then plummeted by 42.07% to $238.9 million in 2025.
  • Its last three reported values are $238.9 million in Q3 2025, $298.2 million for Q2 2025, and $361.3 million during Q1 2025.